Vanderbilt’s Center for Technology Transfer and Commercialization generated nine new companies in 2020 and licensed a significant number of covid-related technologies.
Vanderbilt University’s technology transfer office, the Center for Technology Transfer and Commercialization (CTTC), announced its annual results for 2020 on Wednesday, noting it formed nine spinouts during the year.
The new companies are:
- eFiber Innovation, which produces nanofiber-based materials that address critical needs;
- Elemeno, which develops products for assessing decoding skill and matching children to decodable books;
- HeroWear has created a unisex exosuit that reduces back strain in a variety of work environments;
- IDBiologics focuses on human monoclonal antibodies for the prevention, treatment and cure of infectious diseases;
- Parthenon has turned its attention to cancer therapies;
- DeLeon Biosciences commercialises treatments for inflammation-related bladder disorders, and is also based on research at University of Pittsburgh and University of Pennsylvania;
- EndoTheia is creating next-generation medical devices for endoscopy;
- Arena Therapeutics aims to advance deep brain stimulation to treat early-stage Parkinson’s disease; and
- Yaya Scientific is working on a range of medical devices, including for non-invasive detection and identification of nerves during surgery.
CTTC further noted that all of its activities had surpassed that of previous years despite the challenges of covid. It facilitated 575 outgoing material transfer agreements, 34 of which related to covid-19, and negotiated 86 licences, nine of which were related to the coronavirus.
The university also celebrated 42% of all its invention disclosures in 2020 having at least one female contributor, with the School of Nursing having a female researcher involved for all of its four submissions.
